FLT3 and acute myeloid leukemia: The pivotal RATIFY trial (CALGB 10603) evaluated midostaurin with standard 7+3 induction and high-dose cytarabine consolidation in newly diagnosed AML patients aged 18–59 with FLT3 mutations (ITD-high, ITD-low, or TKD) [52].